FDA panel debates SSRI risk label; APA raises concerns

A recent Food and Drug Administration (FDA) expert panel meeting has reignited debate over the safety of selective serotonin reuptake inhibitors (SSRIs) during pregnancy, with discussions centering on whether to add a Black Box warning to these commonly prescribed antidepressants.